AWAMETOX AB was founded in July 2014 by former AstraZeneca medicinal chemist Alf Claesson. Alf has a broad preclinical experience from more than 27 years in the pharmaceutical industry (AstraZeneca 1984-2010 working as a section head/ project leader/ principal scientist) and academia (Uppsala University, Associate Professor).

During the last years at AstraZeneca he worked as Principal Scientist specializing in chemical toxicology, an interest that he now has taken further into various entrepreneurial endeavours of his own, such as:

a) in 2016  the current SpotRM+ was launched, b) in 2012 he launched the freely available web application SpotRM (now terminated), b) in 2011 set up the site stoprm.org where important literature on RM issues is collated.

SpotRM+ was designed by Alf and developed in collaboration with Genetta Soft, Uppsala (Ola Spjuth in particular). Alf is deeply dedicated to establishing SpotRM+ as the leading tool for drug designers to analyse their chemical structures regarding presence of reactive metabolite motifs.

Alf has published 80+ scientific papers, book chapters and a popular text book on medicinal chemistry (in Swedish). He is co-inventor of many patent applications and holds several patents.

Latest publications

Systematic Approach to Organizing Structural Alerts for Reactive Metabolite Formation from Potential Drugs. A Claesson & A Minidis. Chem Res Toxicol. 2018, 31, 389-411.

On Mechanisms of Reactive Metabolite Formation from Drugs. A Claesson & O Spjuth.  Mini-Rev Med Chem 2013, 13, 720-729.

On the mechanism of paracetamol’s analgesic activity and a note on related NSAID pharmacology. A Claesson on Slideshare 2013 (link).

Reactive Metabolites – Hints How to Avoid a Drug Safety Hazard. Presentation by A Claesson on Slideshare 2012 (link).

Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. RA Thompson, A Claesson et al. Chemico-Biol. Interact. 2011, 192, 65-71.